Nexsen secures HK$6M in non dilutive funding to accelerate clinical validation and manufacturing of its StrepSure® diagnostic in Asia Pacific.
Nexsen advances StrepSure® toward U.S. market entry following FDA Pre Submission feedback that clarifies and de risks its regulatory pathway.
Nexsen (ASX:NXN) has secured $500,000 in non-dilutive Federal funding to extend its rapid Group B Streptococcus diagnostic technology from maternal screening into neonatal testing.
Nexsen has commenced formal engagement with the US Food and Drug Administration for its GBS Rapid Sensor, marking a defined step toward US regulatory clearance under the 510(k) diagnostic pathway.
Nexsen Limited (ASX:NXN) strengthens its global clinical adoption potential with the strategic appointment of internationally recognised surgeon-scientist Professor Shekhar Kumta to its Board.